In between dosesStability throughout the day1,2
Double-blind, randomized single-center, 2-treatment, 2-period, 2-sequence crossover euglycemic clamp study. Evaluated Toujeo® PK/PD at steady state compared with Lantus®.
Patients with type 1 diabetes mellitus (T1DM) (N=30).
Once-daily injections for 8 consecutive days in each treatment period.
On day 8, the dose was followed by a 36-hour euglycemic clamp. Toujeo® in the first treatment period, followed by a washout period and then Lantus® treatment in the second period (or vice versa).
ADA, American Diabetes Association; BG, blood glucose; GIR, glucose infusion rate; PD, pharmacodynamics; PK, pharmacokinetics.
Read the Toujeo® PK/PD study publications at PubMed.gov
For illustration purposes only.